Andrew Brackin
Partner
Gradient
Andrew Brackin is a partner at Gradient, where he invests in vertical AI, healthcare, and application software. Originally from London and now based in San Francisco, California, he led Gradient's seed investment in Vera Health, the AI clinical search tool that more than 800,000 clinicians now use.
Starting as a Thiel Fellow
Brackin was a 2013 Thiel Fellow, one of 20 people worldwide chosen that year to receive $100,000 to build a business in place of going to college, according to his Gradient profile. He began his career at Jobr, a mobile job search app that Monster acquired in 2016.
Building Vial and Newfront
He co-founded Vial, a technology-driven clinical trial company that has raised more than $100 million. He was also the founding head of growth at Newfront, a commercial insurance brokerage that WTW acquired for $1.3 billion in 2025.
Leading the Vera Health Seed
At Gradient, Brackin led the firm's seed investment in Vera Health alongside Garry Tan at Y Combinator. In a March 2026 post he wrote that one weak citation or old guideline "erodes trust in the tool," and that Vera, which ranks sources by how rigorous and relevant they are, had become the fastest-growing clinical AI app in the world.
By October, more than 800,000 clinicians were using Vera, and it had been the most downloaded clinical app every month since June, according to the company's announcement. Gradient tripled down in Vera's Series A. His other investments include Enzo Health, which builds software for home health agencies, and Paladin, which brings AI to emergency response.
Life in San Francisco
Brackin lives in San Francisco and loves politics and live music.